openPR Logo
Press release

Irritable Bowel Syndrome Treatment Market to Reach $2,012 Million by 2026

06-05-2020 03:32 PM CET | Health & Medicine

Press release from: Allied Market Research

Irritable Bowel Syndrome Treatment Market

Irritable Bowel Syndrome Treatment Market

The growth of the irritable bowel syndrome market is attributed to rise in prevalence of gastrointestinal diseases and disorders across the globe. Furthermore, adoption of sedentary lifestyle and launches of various developed pipeline drugs for the irritable bowel syndrome treatment are the other factors that contribute to the growth of the market.

Global Irritable Bowel Syndrome Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).

According to a new report published by Allied Market Research, titled, “Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026”

The irritable bowel syndrome treatment market size was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.

Download PDF Report Sample with statistical info @ https://www.alliedmarketresearch.com/request-sample/6313

Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players profiled in this report include Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/6313

Key Benefits
• The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
• Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework.
• It offers a quantitative analysis to enable the stakeholders to capitalize on the prevailing market opportunities.
• Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
• Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Key Market Segments:

By Type
• IBS with Diarrhea (IBS-D)
• IBS with Constipation (IBS-C)
• Mixed IBS

By Product
• Rifaximin
• Eluxadoline
• Lubiprostone
• Linaclotide
• Others

By End User
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region
• North America
o U.S.
o Canada
o Mexico

• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe

• Asia-Pacific
o Australia
o Japan
o India
o China
o South Korea
o Rest of Asia-Pacific

• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Irritable Bowel Syndrome Treatment Market to Reach $2,012 Million by 2026 here

News-ID: 2068396 • Views:

More Releases from Allied Market Research

Narcotics Scanner Market Analysis and Forecast with a CAGR of 6.6% (2021-2030)
Narcotics Scanner Market Analysis and Forecast with a CAGR of 6.6% (2021-2030)
Narcotics scanner market size was valued at $6.89 billion in 2020, and is projected to reach $12.59 billion by 2030, registering with a CAGR of 6.6% from 2021 to 2030. The growth of the global narcotics scanner market is driven by surge in consumption of drugs and related materials across the globe and modernization of the law enforcement agencies in developing countries. Growing requirement for improved security against the narcotics threats
Herbal Die tary Supplement Market Size, Industry Analysis, Growth Drivers, Opportunities and Leading Players
Herbal Die tary Supplement Market Size, Industry Analysis, Growth Drivers, Oppor …
The herbal die tary supplement market size was valued at $11 billion in 2022, and is estimated to reach $21.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. Herbal die tary supplements are natural items made from plants or plant extracts that are taken to supplement the diet and improve health and well-being. These supplements frequently contain a combination of vitamins, minerals, amino acids, and other
Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion by 2032
Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion …
Allied Market Research published a new report, titled, "Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion by 2032." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain a thorough understanding of the industry and determine
MarTech Market Witnessing CAGR of 18.5% Hit USD 1.7 Trillion by 2032
MarTech Market Witnessing CAGR of 18.5% Hit USD 1.7 Trillion by 2032
The global marketing technology market is experiencing growth due to several factors, including the increasing digital transformation, the surge in demand for personalized experience, and the proliferation of automation and efficiency. However, data privacy and compliance, and the high cost of implementation are expected to hamper market growth. Furthermore, the growing integration of AI and ML technologies and the increase in demand for real-time marketing are anticipated to provide lucrative

All 5 Releases


More Releases for IBS

Irritable Bowel Syndrome (IBS) Treatment Market Poised to Hit $7.68B by 2033 | S …
The Global Irritable Bowel Syndrome (IBS) Treatment Market reached US $3.61 billion in 2024 and is forecast to nearly double to US $7.68 billion by 2033, growing at a robust 8.8% CAGR from 2025 to 2033, according to DataM Intelligence's comprehensive report. IBS affects an estimated 5-10% of the global population, marking it one of the most prevalent gastrointestinal disorders with significant unmet medical needs. 👉 Download our latest market insights:
IBS Implant Market Research Report 2023 - Valuates reports
The global IBS Implant market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes. Get Sample report - https://reports.valuates.com/request/sample/QYRE-Auto-35O11417/Global_IBS_Implant_Market_Research_Report_2022 North American market for IBS Implant is estimated to increase from $ million in 2023 to reach $ million by 2029, at
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide. A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped